阿尔茨海默病的A2G plus管理模式

A2G plus management model for Alzheimer's disease

当我们临床医师似乎已经学会了应用各种最新权威指南一致推荐的有理有据的食品药品监督管理局（Food and Drug Administration,FDA）批准的阿尔茨海默病（Alzheimer’s disease,AD）一线治疗药物乙酰胆碱酯酶抑制剂（acetylcholinesterase inhibitors,ACh EI）及谷氨酸NMDA受体（N-methyl-D-aspartic acid receptor）拮抗剂治疗痴呆时,

With the aging of society and the development of medically diagnostic techniques, the incidence and diagnosis rate of Alzheimer＇ s disease （AD） have been increasing. However, there is no breakthrough in the treatment of AD at present. Thus, it is necessary to explore the optimal management for AD patients under the current condition. AD is characterized by multi-target mechanisms of pathogenesis and complexity of clinical symptoms, which requires more comprehensive treatment and management. Here, we elaborate of A2G plus （ one or more of A to G and other plus measures） comprehensive management model for AD patients. This model is built upon 4 international authoritative guidelines, multi-target mechanisms of disease, existing therapeutic drugs and methods, and long-term clinical experiences and patient＇ s individual condition, and provides a new model of comprehensive treatment and management for AD patients.